Xenova Acquires KS Biomedix to Focus on Brain Cancer Drug
Business Review Editor
Abstract
Xenova entered into an agreement to acquire KS Biomedix, thus substantially expanding its Brain cancer drug product portfolio.
Full Text: pdf
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.